Clarithromycin-Susceptible But Virulent Helicobacter pylori Strains Infecting Iranian Patients’ Stomachs

References

• Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347(15):1175–1186. doi:10.1056/NEJMra02054212374879
   PubMed Web of Science ®Google Scholar
• Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345(11):784–789. doi:10.1056/NEJMoa00199911556297
   PubMed Web of Science ®Google Scholar
• Yamaoka Y. Mechanisms of disease: helicobacter pylori virulence factors. Nat Rev Gastroenterol Hepatol. 2010;7(11):629. doi:10.1038/nrgastro.2010.15420938460
   PubMed Web of Science ®Google Scholar
• Brennan DE, Dowd C, O’Morain C, McNamara D, Smith SM. Can bacterial virulence factors predict antibiotic resistant Helicobacter pylori infection? World J Gastroenterol. 2018;24(9):971. doi:10.3748/wjg.v24.i9.97129531461
   PubMed Web of Science ®Google Scholar
• Crabtree J, Wessler S. Special Issue “H. pylori Virulence Factors in the Induction of Gastric Cancer. Multidisciplinary Digital Publishing Institute; 2018.
   Google Scholar
• Kabamba ET, Yamaoka Y. Helicobacter pylori and related virulence factors for gastrointestinal diseases. Gastr Cancer (Springer). 2019;31–50.
   Google Scholar
• Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med. 1995;333(15):984–991. doi:10.1056/NEJM1995101233315087666920
   PubMed Web of Science ®Google Scholar
• den Hoed CM, Kuipers EJ Helicobacter pylori infection. Hunter’s Tropical Medicine and Emerging Infectious Diseases: Elsevier; 2020:476–480.
   Google Scholar
• Goderska K, Pena SA, Alarcon T. Helicobacter pylori treatment: antibiotics or probiotics. Appl Microbiol Biotechnol. 2018;102(1):1–7. doi:10.1007/s00253-017-8535-729075827
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6–30.27707777
   PubMed Web of Science ®Google Scholar
• Uotani T, Miftahussurur M, Yamaoka Y. Effect of bacterial and host factors on Helicobacter pylori eradication therapy. Expert Opin Ther Targets. 2015;19(12):1637–1650. doi:10.1517/14728222.2015.107326126245678
   PubMed Web of Science ®Google Scholar
• Thung I, Aramin H, Vavinskaya V, et al. the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43(4):514–533. doi:10.1111/apt.1349726694080
   PubMed Web of Science ®Google Scholar
• Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology. 1998;115(5):1272–1277. doi:10.1016/S0016-5085(98)70100-39797384
   PubMed Web of Science ®Google Scholar
• Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112(2):212. doi:10.1038/ajg.2016.56328071659
   PubMed Web of Science ®Google Scholar
• Fischbach L, Evans E. Meta‐analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first‐line therapies for Helicobacter pylori. Aliment Pharmacol Ther. 2007;26(3):343–357. doi:10.1111/apt.2007.26.issue-317635369
   PubMed Web of Science ®Google Scholar
• Rimbara E, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol. 2011;8(2):79. doi:10.1038/nrgastro.2010.21021293508
   PubMed Web of Science ®Google Scholar
• Broutet N, Tchamgoue S, Pereira E, Lamouliatte H, Salamon R, Megraud F. Risk factors for failure of Helicobacter pylori therapy—results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther. 2003;17(1):99–109. doi:10.1046/j.1365-2036.2003.01396.x12492738
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection—the Maastricht IV/Florence consensus report. Gut. 2012;61(5):646–664. doi:10.1136/gutjnl-2012-30208422491499
   PubMed Web of Science ®Google Scholar
• Federico A, Gravina AG, Miranda A, Loguercio C, Romano M. Eradication of Helicobacter pylori infection: which regimen first? World J Gastroenterol. 2014;20(3):665. doi:10.3748/wjg.v20.i3.66524574740
   PubMed Web of Science ®Google Scholar
• Asokan GV, Vanitha A. WHO global priority pathogens list on antibiotic resistance: an urgent need for action to integrate one health data. Perspect Public Health. 2018;138(2):87–88. doi:10.1177/175791391774388129465015
   PubMed Web of Science ®Google Scholar
• Miyachi H, Miki I, Aoyama N, et al. Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan. Helicobacter. 2006;11(4):243–249. doi:10.1111/hel.2006.11.issue-416882327
   PubMed Web of Science ®Google Scholar
• Mendonça S, Ecclissato C, Sartori M, et al. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil. Helicobacter. 2000;5(2):79–83. doi:10.1046/j.1523-5378.2000.00011.x10849055
   PubMed Web of Science ®Google Scholar
• Mégraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev. 2007;20(2):280–322. doi:10.1128/CMR.00033-0617428887
   PubMed Web of Science ®Google Scholar
• Tanih NF, McMillan M, Naidoo N, Ndip LM, Weaver LT, Ndip RN. Prevalence of Helicobacter pylori vacA, cagA and iceA genotypes in South African patients with upper gastrointestinal diseases. Acta Trop. 2010;116(1):68–73. doi:10.1016/j.actatropica.2010.05.01120529658
   PubMed Web of Science ®Google Scholar
• Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 2006;19(3):449–490. doi:10.1128/CMR.00054-0516847081
   PubMed Web of Science ®Google Scholar
• Jafari F, Shokrzadeh L, Dabiri H, et al. vacA genotypes of Helicobacter pylori in relation to cagA status and clinical outcomes in Iranian populations. Jpn J Infect Dis. 2008;61(4):290.18653971
   PubMed Web of Science ®Google Scholar
• Chomvarin C, Namwat W, Chaicumpar K, et al. Prevalence of Helicobacter pylori vacA, cagA, cagE, iceA and babA2 genotypes in Thai dyspeptic patients. Int J Infect Dis. 2008;12(1):30–36. doi:10.1016/j.ijid.2007.03.01217548220
   PubMed Web of Science ®Google Scholar
• Zamani M, Ebrahimtabar F, Zamani V, et al. Systematic review with meta‐analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018;47(7):868–876. doi:10.1111/apt.1456129430669
   PubMed Web of Science ®Google Scholar
• Miftahussurur M, Yamaoka Y, Graham DY. Helicobacter pylori as an oncogenic pathogen, revisited. Expert Rev Mol Med. 2017;19.
   Web of Science ®Google Scholar
• Lee Y-C, Chen T-H-H, Chiu H-M, et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut. 2013;62(5):676–682. doi:10.1136/gutjnl-2012-30224022698649
   PubMed Web of Science ®Google Scholar
• Ansari S, Yamaoka Y. Survival of Helicobacter pylori in gastric acidic territory. Helicobacter. 2017;22(4):e12386. doi:10.1111/hel.2017.22.issue-4
   Web of Science ®Google Scholar
• Knorr J, Ricci V, Hatakeyama M, Backert S. Classification of Helicobacter pylori virulence factors: is CagA a toxin or not? Trends Microbiol. 2019;27:731–738. doi:10.1016/j.tim.2019.04.01031130493
   PubMed Web of Science ®Google Scholar
• Khashei R, Dara M, Bazargani A, et al. High rate of A2142G point mutation associated with clarithromycin resistance among Iranian Helicobacter pylori clinical isolates. Apmis. 2016;124(9):787–793. doi:10.1111/apm.2016.124.issue-927357065
   PubMed Web of Science ®Google Scholar
• Mahmoudi S, Mamishi S, Banar M, et al. Antibiotic susceptibility of Helicobacter pylori strains isolated from Iranian children: high frequency of A2143G point mutation associated with clarithromycin resistance. J Glob Antimicrob Resist. 2017;10:131–135. doi:10.1016/j.jgar.2017.04.01128720314
   PubMed Web of Science ®Google Scholar
• Pourakbari B, Mahmoudi S, Parhiz J, Sadeghi R, Monajemzadeh M, Mamishi S. High frequency of metronidazole and clarithromycin-resistant Helicobacter pylori in formalin-fixed, paraffin-embedded gastric biopsies. Br J Biomed Sci. 2018;75(2):61–65. doi:10.1080/09674845.2017.139146629452048
   PubMed Web of Science ®Google Scholar
• Alarcón-Millán J, Fernández-Tilapa G, Cortés-Malagón EM, et al. Clarithromycin resistance and prevalence of Helicobacter pylori virulent genotypes in patients from Southern México with chronic gastritis. Infect Genet Evol. 2016;44:190–198. doi:10.1016/j.meegid.2016.06.04427355861
   PubMed Web of Science ®Google Scholar
• Bagheri N, Azadegan-Dehkordi F, Rafieian-Kopaei M, Rahimian G, Asadi-Samani M, Shirzad H. Clinical relevance of Helicobacter pylori virulence factors in Iranian patients with gastrointestinal diseases. Microb Pathog. 2016;100:154–162. doi:10.1016/j.micpath.2016.09.01627666510
   PubMed Web of Science ®Google Scholar
• Gilani A, Razavilar V, Rokni N, Rahimi E VacA and cagA genotypes of Helicobacter pylori isolated from raw meat in Isfahan province, Iran. Paper presented at: Veterinary Research Forum 2017.
   Google Scholar
• Ranjbar R, Khamesipour F, Jonaidi‐Jafari N, Rahimi E. Helicobacter pylori isolated from Iranian drinking water: vacA, cagA, iceA, oipA and babA2 genotype status and antimicrobial resistance properties. FEBS Open Bio. 2016;6(5):433–441. doi:10.1002/2211-5463.12054
   PubMed Web of Science ®Google Scholar
• Bachir M, Allem R, Tifrit A, et al. Primary antibiotic resistance and its relationship with cagA and vacA genes in Helicobacter pylori isolates from Algerian patients. Braz J Microbiol. 2018;49(3):544–551. doi:10.1016/j.bjm.2017.11.00329452847
   PubMed Web of Science ®Google Scholar